Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpALA: Avelumab and Aspirin in Triple-Negative Breast Cancer
NCT03794596Phase 2Withdrawn
- Sponsor
- The Christie
- Start
- Sep 2019
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of avelumab in triple-negative breast cancer (TNBC), sponsored by The Christie. Primary endpoint: Mean combined gene expression of COX-2 tumour-promoting genes at 7 weeks. Planned start Sep 2019; status: withdrawn.
02
Drugs
avelumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03794596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03794596.